Champions Oncology: the profit plunge was a one-time deal, but the stock isn't cheap on what's left

Champions Oncology (CSBR) reported the first quarter of its new fiscal year on Thursday, and on the surface it is the kind of number a first-time investor might wave away. Revenue rose 8.8% to $15.2 million, the company still lost money on a GAAP basis — a $426,000 net loss — and cash on the balance sheet has now slipped to about $4.4 million. It is a small, illiquid, sell-rated biotech research firm trading near $5 a share, roughly $70 million in total market value.

But the quarter is doing something more interesting than that headline suggests, and to see it you have to untangle a number from the year before that made the last full year look like a collapse when it mostly was not.

The "profit to loss" year was a one-time deal, not a breakdown

The fiscal 2026 income statement (the year that ended April 30, 2026) looked ugly. GAAP earnings swung from a $4.7 million profit in the prior year to a $1.18 million loss. Adjusted EBITDA — a profit measure that adds back stock-based pay and depreciation — fell from $7.1 million to $1.6 million. Read that list and the natural conclusion is a company falling apart.

The problem is that a big chunk of the prior year's profit came from a single, non-recurring data-license deal worth about $4.5 million that does not repeat. Data-license revenue collapsed from roughly that level down to about $800,000 this year. Strip that one-time windfall out of both years and the picture changes: the core research-services business — the company's actual business — grew about 12% to a record $58.7 million. Fiscal 2026 was not a breakdown. It was the year the company stopped getting paid for a lump sum it had earned once.

That distinction matters, because it is the difference between a company whose growth is stalling and one whose growth is being hidden by an accounting artifact.

The margin is quietly getting better

The encouraging part of Thursday's report sits on the margin line, not the revenue line. The research-services margin — the share of services revenue that stays after direct costs — jumped to 51% from 43% a year earlier. Adjusted EBITDA climbed to $671,000 from $59,000. Costs rose 7.7%, a little slower than the 8.8% revenue growth, and management attributes the margin recovery to moving radiopharmaceutical work in-house instead of outsourcing it, plus a bit of operating leverage from not adding much headcount.

None of that is large yet. $671,000 of quarterly EBITDA on $15 million of revenue is a company sitting at breakeven, not one printing cash. The direction is right; the size is still small. That gap — improving quality, tiny profit — is exactly where the valuation problem begins.

"Cheap" on sales is not "cheap" on the money it actually makes

This is the part a first-time investor tends to get wrong, so it is worth being precise about. At a roughly $70 million market cap, Champions trades at about 1.2 times its $59.4 million of fiscal 2026 revenue. On that basis the stock looks cheap — many growing software and healthcare companies sell at several times their sales.

But that same $70 million is about 43 times the company's $1.6 million of fiscal 2026 adjusted EBITDA, which is not cheap at all. It is the multiple of a company expected to grow its earnings a great deal.

Both numbers are real. A stock can be inexpensive relative to its revenue and still expensive relative to its profit, and the only way to tell which number is doing the work is to ask where the profit is heading. Right now Champions sits on the expensive side of that split: it is spending hard to build a future — research and development rose 33% to $9.1 million and sales and marketing rose 23% to $9.3 million last year — while the present barely breaks even. "Cheap on sales" only becomes a buy if you believe that spending converts into a much bigger EBITDA. As it stands, you are paying a rich earnings multiple for a story that is improving but has not yet proven out.

The number that could change the read: cash

The most concrete risk here is not the margin or the growth — it is the balance sheet. Cash has fallen from $9.8 million at the end of the prior fiscal year, to $4.9 million at the end of fiscal 2026, to $4.4 million now. There is no debt, which is a plus, but there is also no cushion to fall back on.

And the company is not done spending. Management is building out the in-house radiopharmaceutical platform, expanding its data business, and growing its sales team. On top of that it runs a separate therapeutic subsidiary, Corellia, that is burning cash to develop its own drug candidates — and the company is now openly looking for outside funding or a licensing deal to support it. A small research firm also funding an unproven drug pipeline is a real cash drain, and if the services business does not scale fast enough to out-earn that burn, the eventual answer may be a dilutive raise. That is the fact a buyer has to be comfortable with, and it is the fact that could turn this from a wait into a problem.

Where that leaves you

The honest read is "too early," and the market's own consensus — an average sell rating — already leans that way. The relief about fiscal 2026's ugly headline is that it was largely an artifact, and the underlying services business is genuinely improving on margin. But improvement on a base of $1.6 million of EBITDA, against a cash balance that is halving, at a multiple that is rich on earnings and priced for a turnaround, is not a cheap-enough bridge. The stock is not being sold on fear the way a bargain is; it is being held at its level on a story that has not yet shown up in the cash.

Over the next two to four quarters the question is narrow. Does the services margin keep climbing above 51%? Does revenue growth hold up through the lumpy timing of study completions — above the low single digits? And, most importantly, does the cash balance stop eroding, ideally because the in-house radiopharma work is now appearing as higher margin rather than just higher cost? If you see all three, that rich EBITDA multiple starts to look like a reasonable bet on a recovery. If the cash keeps sliding and growth stalls in the low single digits, the "one-time deal" explanation of the bad year stops mattering, and the underlying business is simply slow with a thin balance sheet. Until one of those becomes visible, the operating insight — better margin, thin profit, shrinking cash — is enough; the stock is a watch, not a call.